Knight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan purchased 17,600 shares of the business's stock in a transaction on Tuesday, March 4th. The stock was purchased at an average price of C$5.48 per share, for a total transaction of C$96,488.48.
Knight Therapeutics Stock Down 1.3 %
Shares of GUD stock traded down C$0.07 during trading hours on Friday, reaching C$5.48. The company had a trading volume of 50,231 shares, compared to its average volume of 52,683. Knight Therapeutics Inc. has a 12 month low of C$5.09 and a 12 month high of C$6.23. The company has a debt-to-equity ratio of 7.52, a current ratio of 3.36 and a quick ratio of 1.79. The business has a fifty day simple moving average of C$5.54 and a 200-day simple moving average of C$5.55. The company has a market cap of C$554.30 million, a price-to-earnings ratio of -18.29, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50.
Wall Street Analyst Weigh In
Separately, Raymond James upgraded Knight Therapeutics to a "moderate buy" rating in a report on Friday, November 15th.
Get Our Latest Analysis on GUD
About Knight Therapeutics
(
Get Free Report)
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Featured Stories
Before you consider Knight Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Knight Therapeutics wasn't on the list.
While Knight Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
